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SIGNIFICANCE STATEMENT: Nanoparticles are being produced for an ever-15 
increasing range of applications and with such growth comes a need to efficiently assess 16 
any potential toxicity associated with these new materials. Here we describe in detail a 17 
step-by-step protocol that can be used to rapidly and effectively assess nanotoxicity, by 18 
combining mammalian cytotoxicity assessment with vertebrate abnormality scoring 19 
using X. laevis embryos. We have previously demonstrated that this approach is 20 
effective at determining low-toxicity nanomaterials in mice (Webster et al., 2016). This 21 
protocol can be used as a rapid screening approach for newly developed nanomaterials, 22 
with high predictive power for determining nanoparticle safety in vertebrate systems.  23 
 2 
 24 
ABSTRACT  25 
 26 
The African clawed frog, Xenopus laevis, has been used as an efficient pre-clinical screening 27 
tool to predict drug safety during the early stages of the drug discovery process. X. laevis is a 28 
relatively inexpensive model that can be used in whole organism high-throughput assays 29 
whilst maintaining a high degree of homology to the higher vertebrate models often used in 30 
scientific research. Despite an ever-increasing volume of biomedical nanoparticles (NPs) in 31 
development, their unique physico-chemical properties challenge the use of standard 32 
toxicology assays. Here, we present a protocol that directly compares the sensitivity of X. 33 
laevis development as a tool to assess potential NP toxicity by observation of embryo 34 
phenotypic abnormalities/lethality after NP exposure to in vitro cytotoxicity obtained using 35 
mammalian cell lines. In combination with conventional cytotoxicity assays, the X. laevis 36 
phenotypic assay provides accurate data to efficiently assess the safety of a novel biomedical 37 
NP.  38 
 39 
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The research and application of biomedical NPs is a rapidly evolving discipline (De Jong and 45 
Borm, 2008). For many, it is believed that biomedical nanomaterials can act as advantageous 46 
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tools in the treatment of several disease states. In particular, the unique physico-chemical 47 
properties of NPs makes them an ideal therapeutic and diagnostic tool in oncology by 48 
overcoming the limitations of conventional therapies, as we have previously discussed 49 
(Bombelli et al., 2014). The main advantages of using biomedical NPs as drug delivery 50 
systems include targeted drug delivery, increased biocompatibility and a decrease in drug 51 
toxicity, whilst maintaining or improving the therapeutic effect. However, as a result of the 52 
high surface area-to-ratio volume and complex composition of the nanomaterial, NPs can be 53 
highly reactive, where combinations of NP size, shape, material, and functionalisation, can 54 
result in toxicity within a biological systems (Lewinski et al., 2008; Nystrom and Fadeel, 55 
2012).  56 
 57 
Conflicting information regarding NP safety for a given material can impede the progression 58 
of a NP from the early stages of formulation development through to the clinic. 59 
Inconsistencies in NP toxicity data are largely attributable to a lack of a standardised protocol 60 
for nanotoxicity assessment. Firstly, full characterisation of a NP system (including size, 61 
surface charge, and stability in assay buffers) is required to understand the fate of the NP in a 62 
biological system and its potential to cause toxicity. Different early developmental models, 63 
such as Xenopus species (Bacchetta et al., 2014; Hu et al., 2016; Mouchet et al., 2008; 64 
Tussellino et al., 2015; Webster et al., 2016) and zebrafish (George et al., 2011; Liu et al., 65 
2012; Rizzo et al., 2013), have been explored as systems that can provide rapid, accurate, cost 66 
effective and abundant data for NP toxicology assessment. X. laevis (the African clawed frog) 67 
is a species that produce large quantities of embryos allowing them to be used in a high-68 
throughput style assay to gain toxicology data relatively quickly. Furthermore, with an 69 
individual embryo size at early developmental stages of ~1 mm, they are well suited for use 70 
in a multi-well format. X. laevis has the advantage of being evolutionary closer to humans 71 
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than other early models such as Caenorhabditis elegans, Drosophila, and zebrafish (Wheeler 72 
and Brandli, 2009). Although mouse models, as the gold standard, are evolutionary closer to 73 
humans than X. laevis, they are expensive and not a viable option to test numerous NPs over 74 
a wide range of concentrations, as far fewer embryos are produced compared to X. laevis.  75 
 76 
Here we provide a detailed protocol for the use of X. laevis embryos in conjunction with 77 
cytotoxicity analysis, for highlighting potential NP toxicity by observing phenotypic 78 
abnormalities/lethality in response to NP exposure. X. laevis development is well documented 79 
(Nieuwkoop and Faber, 1967), making it easy to detect when toxicity-induced deviation from 80 
normal embryo development has occurred. The rationale for this approach has previously 81 
been described (Webster et al., 2016) and involves a combined assessment of cytotoxicity 82 
with X. laevis abnormality assessment in response to NP treatment, which offers a sensitive 83 
nanotoxicity model to bridge standard in vitro assessment alone with further rodent testing 84 
(Fig. i).  Specifically, this methodology incorporates physicochemical characterization of 85 
nanomaterials, followed by rapid cytotoxicity and phenotypic abnormality assessment as an 86 
indicator of nanotoxicity prior to later testing in mammalian systems. 87 
 88 
BASIC PROTOCOL 1 – PHYSICOCHEMICAL CHARACTERISATION OF NPs  89 
This protocol describes the necessary steps to prepare nanoparticle (NP) dispersions suitable 90 
for toxicological characterization by cytotoxicity and X. laevis phenotypic scoring assays. 91 
This protocol is designed to be adaptable to different types of nanoformulations (thus it is not 92 
addressed to a specific typology of NPs), but is to be used for NPs dispersed in aqueous 93 
solutions. Physical-chemical characterization of NP dispersions is a critical step in a nano-94 
safety assessment protocol (Azhdarzadeh et al., 2015), in particular the experiments need to 95 
be performed not only in the NP dispersion medium, but also in the fluids in which the NPs 96 
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will be dispersed during the biological assays. It is also important to monitor the colloidal 97 
stability of the NP dispersions over the duration of the nanotoxicity assessment period to 98 
detect any potential agglomeration effects over time (Cho et al., 2013). Generally, NP 99 
dispersions are commonly characterized in terms of hydrodynamic size of the particles 100 
through Dynamic Light Scattering (DLS) measurements. To better interpret DLS results it is 101 
also necessary to perform Transmission Electron Microscopy (TEM) on the dried samples for 102 
evaluating the morphology and size of a single NP. The presence of biomolecules (i.e. 103 
proteins) in the biological fluids affects the DLS results by producing a background signal, 104 
thus such experiments should be performed at a maximum protein concentration used in the 105 
nanotoxicity experiments (i.e. 10% v/v serum used in GM), but not in pure serum as in that 106 
case the protein signal overcomes that deriving from the NPs. Moreover, it has been shown 107 
that the presence of proteins or other biomolecules in the biological fluids affects the 108 
physical-chemical properties of the NPs through the formation of a protein corona around the 109 
NPs (Cedervall et al., 2007; Monopoli et al., 2012). Thus, the analysis of DLS data in 110 
biological fluids can be more complex than in physiological buffer solutions. In fact, even if 111 
DLS is a good technique for testing the stability of NP dispersions in biological fluids, it does 112 
not give a quantitative estimation of the size of such complexes (as it cannot distinguish 113 
among dimer, trimer or agglomerates of protein-NP complexes). For this purpose it would be 114 
necessary to implement the NP characterization with different analysis such as Differential 115 
Centrifugal Sedimentation (Walczyk et al., 2010) or Fluorescence Correlation Spectroscopy 116 
(Rocker et al., 2009), which is beyond the interest of this protocol.   117 
 118 
Materials  119 
 120 
NP stock dispersions (concentrations and nanomaterials tested are to be pre-determined 121 
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 by the experimenter) 122 
Disposable DLS cuvettes  123 
Dynamic Light Scattering apparatus   124 
PBS (see recipe) 125 
Mammalian cell culture growth media (GM; see basic protocol 2 for further details) 126 
0.1X Marc’s Modified Ringer’s (MMR; see recipe) 127 
 128 
1.  Prepare the DLS cuvettes cleaning them with autoclaved Milli-Q-purified H20 (d.H20) 129 
and then dry with particular care to protect them from dust.  130 
2. Transfer the NP dispersions to the DLS cuvettes (necessary volume depends on the 131 
DLS apparatus) and dilute them if it is necessary. The solvent used to dilute the NP 132 
dispersions must be dust free as much as possible.  133 
IMPORTANT NOTE: Never touch the middle-bottom part of the cuvettes with hands, 134 
but always manage them touching them in their upper edge.  135 
The choice of the optimal concentration for DLS measurements should be based on 136 
both experimental and technical considerations. A concentration as much as possible 137 
similar to those used in the biological assays should be chosen (usually the most 138 
concentrated dose used in vitro is the safest choice to detect possible NP 139 
agglomeration).  140 
It is recommended to run a quick test for evaluating the averaged scattered intensity of 141 
the chosen dilution that should be above 20 kcounts/s for be statically significant. If it is 142 
lower than that value, a more concentrated sample should be prepared.  143 
3. Set the temperature to the desired value according to that at which the biological 144 
experiments are performed. 145 
 In this context these temperatures will be 37°C for mammalian and 12-23°C for X. 146 
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laevis work.  147 
4.  The NP dispersion in the cuvette should be left to rest in the sample holder for 148 
approximately 10 minutes before the measurement to reach the desired temperature and allow 149 
the eventual dust to sediment.    150 
5.  Measure the scattered intensity at a set angle of detection. Generally, the most used 151 
apparatus can measure the scattered intensity at a fixed angle (either 90° or 173°), but there 152 
are also more advanced instruments that permit multi-angle detection, in that case it is better 153 
to measure the scattered intensity at different angles (Fig ii). The detected signal will be 154 
automatically sent to the correlator, which produces the auto-correlation function of the 155 
scattered intensity g2(q,t) for each angle (equation 1):  156 
  157 
 158 




…is the scattering vector (with θ the detection angle, λ the wavelength of the incident light 163 
and n the solvent refractive index).  164 
2 Analyze the auto-correlation functions to extract the NP hydrodynamic size by available 165 
analysis softwares. The analysis of the auto-correlation functions at each angle gives a 166 
decay rate Γ(s-1) related to the NP dynamics and related to the translational diffusion 167 
coefficient, D, through the following equation for Brownian systems (equation 2):  168 
  169 
Γ(s-1)=D∙q2        (2)  170 
                                                                                   171 
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 Thus reporting the decay rates versus the scattering vectors the slope of the obtained curve is 172 
the translation diffusion coefficient. The NP hydrodynamic radius, rH, can be determined 173 
through the Stokes-Einstein relationship (equation 3):  174 
 175 
D=kBT/6πρrH        (3)  176 
 177 
Where T is the experimental temperature and ρ the viscosity of the solvent.   178 
IMPORTANT NOTE: the fitting analysis of the auto-correlation functions for 179 
determining the decay rates must be carefully chosen. If the auto-correlation 180 
function is monomodal (the sample is mostly composed of a single population of NPs 181 
of the same size), a Cumulant method (Koppel, 1972) can be used. This fitting 182 
analysis gives an averaged < Γ> together with a polydispersity index (PDI). If the 183 
PDI is <0.2-0.25, it is reasonable to use this method. If the PDI is >0.25 the sample 184 
is either very polydisperse or composed of two or more populations and an 185 
alternative method must be used. The most common is the algorithm 186 
CONTIN (Provencher, 1982)-based on the Laplace transform of the auto-187 
correlation function. This method gives a size-distribution of the NP dispersion 188 
distinguishing different particle populations differing in scattered intensities of at 189 
least 1:10-5. For monomodal polydisperse samples the two methods should give 190 
comparable results.  191 
  192 
SUPPORT PROTOCOL 1 – TEM FOR NP CHARACTERISATION   193 
 As highlighted in Basic Protocol 1, a TEM study should be done on the NP stock dispersion 194 
for evaluating NP morphology and better interpreting DLS results. TEM analysis allows the 195 
determination of the size of single NPs that can be used for understanding the NP size 196 
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distribution obtained by DLS and highlight possible agglomeration effects. TEM equipment 197 
comprises of complex instrumentation and usually a dedicated person(s) is/are responsible for 198 
its maintenance and running experiments in a core facility within institutions. Thus, here we 199 
only describe a protocol for preparing samples to be measured by TEM. It is necessary to 200 
prepare a dispersion of the NPs in d.H2O as the sample has to be dried (measurements are 201 
performed in vacuum) and salt crystallization can occur if the NPs are dispersed in buffer 202 
affecting the experiment. If the NP stock is dispersed in buffer, it is also possible to wash the 203 
sample directly on the grid.  204 
  205 
Materials  206 
 207 
TEM grid (the chosen material depends of the NP material and the specifics of the 208 
apparatus and manufacturer) 209 
TEM instrument with imaging modality 210 
NP stock dispersions (concentrations and nanomaterials tested are to be pre-211 
determined by the experimenter) 212 
1. Wash the grid with a suitable clean solvent as indicated by the supplier (it depends on 213 
the material of the grid).  214 
IMPORTANT NOTE: Never touch the grid with hands but always use suitable 215 
tweezers.   216 
2. Transfer the NP dispersion onto the grid by multiple depositions of 5-10 μl. After 217 
each deposition let the solvent evaporate before adding the following drop.  218 
If it is necessary (i.e. if the NPs are dispersed in salt solutions) wash the grid with 219 
d.H2O to eliminate the salts as this operation should not remove the NPs, which are 220 
adhered to the grid surface.  221 
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A rough calculation of the amount of NPs transferred to the grid should be done for 222 
evaluating the number of depositions necessary to reach the minimum amount of 223 
sample to perform a statistically significant measure.  224 
3.  Leave the grid to dry overnight, ideally under a hood and protected from dust.   225 
4. Perform the measurement taking pictures of different areas on the grid.   226 
5.  For each grid (sample) several images are taken and saved. The images are analyzed 227 
with specific image software that allow extracting size information, thus a size-228 
distribution can be determined. 229 
IMPORTANT NOTE: To be statistically meaningful the size-distribution must be 230 
done on at least 100 NPs.  231 
TEM size is often 10% smaller than the hydrodynamic size that also includes the 232 
hydration layer. 233 
 234 
BASIC PROTOCOL 2 – CYTOTOXICITY ASSESSMENT OF NP TREATMENT  235 
A crucial part of our nanotoxicity protocol is cytotoxicity assessment in mammalian cells, as 236 
due to their unique material composition, some nanoformulations can have harmful toxic 237 
effects in mammalian systems. Multiple factors can influence the extent of nanomaterial 238 
toxicity such as NP size, morphology, chemical structure and surface chemistry (Caballero-239 
Diaz and Valcarcel Cases, 2016). A wide variety of conventional in vitro assays are available 240 
to assess nano-cytotoxicity, for example; 3-(4,5 dimethylthiazol)-2,5 diphenyltetrazolium 241 
bromide (MTT), which is a commonly used cytotoxicity assessment assay that has been 242 
successfully used to detect nanotoxicity (Gulati et al., 2010; Hussain et al., 2005; Park et al., 243 
2010; Schubert et al., 2006; Webster et al., 2016; Yuan et al., 2010) and provides a simple, 244 
reproducible and reliable test set-up. In addition to MTT, nanotoxicity in mammalian cells 245 
can be evaluated by a variety of other cytotoxicity assessment methods including; 2′,7′-246 
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Dichlorofluorescein (DFC) assay, proinflammatory cytokine ELISA, TUNEL, Trypan Blue 247 
Exclusion assay, (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-248 
sulfophenyl)-2H-tetrazolium; MTS), CellTiter-Glo, adenosine triphosphate luminiscence, 249 
alamar blue (resazurin assay), neutral red staining, lactate dehydrogenase content analysis, 250 
phosphatidylserine translocation monitored by Annexin V staining, mitochondrial membrane 251 
potential and apoptotic protein level/activity, to name several.  252 
 253 
Depending on their specific NPs and experimental conditions, users can select cytotoxicity 254 
methodologies to suit, as some nanoformulations can affect cytotoxicity readings by certain 255 
experimental approaches (Belyanskaya et al., 2007; Davoren et al., 2007; Hillegass et al., 256 
2010; Monteiro-Riviere et al., 2009; Wang et al., 2011). Two or more cytotoxicity protocols 257 
need to be employed to ensure that the nanotoxicity assessment is robust, which ideally 258 
should test more than one of the following cytotoxicity assessment parameters; oxidative 259 
stress, cell death, cell viability and inflammatory response. Table i provides a list of 260 
conventional cytotoxicity assessment assays and which NPs are compatible with these 261 
methods.  Here we describe a protocol that we have previously used for NP cytotoxicity 262 
assessment to analyse cell viability using two methods; MTT and Trypan Blue Exclusion 263 
assay (support protocol 2), and cell death by assessing apoptotic markers (support protocol 264 
3). 265 
 266 
Materials  267 
 268 
Mammalian cell lines of choice (recommended a minimum of 3 should be used) 269 
Liquid N2 cryogenic cell storage Dewar flask (for long-term storage of cell stocks; 270 
Cole-Palmer) 271 
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Water bath (set to 37 oC; Fisher Scientific; an anti-microbial agent should be added to 272 
the water tray to limit contamination) 273 
GM containing supplements as required (e.g. foetal bovine serum, amino acids, 274 
antibiotics etc., as required depending on the chosen cell types. GM details 275 
for specific lines are provided by the supplier or in the scientific literature. 276 
All reagents must be cell culture grade) 277 
70% ethanol (Sigma-Aldrich) 278 
Class II biological safety cabinet (Monmouth Scientific)  279 
Sterile, disposable cell culture plastic ware (including flasks, plates, tubes, tips etc. 280 
For adherent cells, flasks and plates must be cell culture grade) 281 
Humidified 37 oC, 5% CO2 cell culture incubator (New Brunswick; an anti-microbial 282 
agent should be added to the water tray to limit contamination) 283 
Inverted light microscope (Olympus) 284 
Phosphate buffered saline (PBS; see recipe) 285 
0.05% (w/v) Trypsin-EDTA solution (cell culture grade; Sigma-Aldrich) 286 
Swing-out (bucket) centrifuge (Eppendorf) 287 
Automated cell counter (e.g. Bio-Rad TC20TM) or a Neubauer hemocytometer (Merck 288 
Millipore) 289 
Mycoplasma testing kit (we use the EZ-PCR mycoplasma test kit; Gene Flow) 290 
Multichannel pipette (Fisher Scientific) 291 
NP exposure solution (concentrations and nanomaterials tested are to be pre-292 
determined by the experimenter) 293 
MTT solution (Sigma-Aldrich; prepared according to the manufacturer’s instructions) 294 
Dimethyl sulfoxide (DMSO; Sigma-Aldrich) 295 
Sorensen’s glycine buffer (see recipe) 296 
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Microplate spectrophotometer reader (SpectraMax) 297 
 298 
1. Resuscitate mammalian cells from cryopreservation. Grow according to 299 
recommendations for the chosen cell lines, according to good lab practice (GLP). Correct 300 
handling and GLP for cell culturing involves the use of aseptic technique to avoid 301 
contamination of the cultures (Freshney, 2010). Furthermore, cells should be used at low 302 
passage numbers (<25) to avoid genetic drift and lines should be validated, and checked for 303 
contaminants prior to experimental use. 304 
Three or more cell lines should be selected by the experimenter to assess nanotoxicity. 305 
The selection of these lines should be based upon the predicted exposure routes of the 306 
nanomaterial being assessed. For example, we have previously assessed iron oxide 307 
NP cytotoxicity in cell lines that represent possible exposure tissues in man, i.e. lung 308 
epithelium (A549), skin (SK-MEL-28) and kidney epithelium (MDCK), and that are 309 
easy to grow (Webster et al., 2016).  310 
Supplementation of GM with antibiotics is optional. If it is used we recommend 100 311 
μg/ml penicillin/streptomycin. 312 
IMPORTANT NOTE: GM is prepared in advance and can be used for several weeks 313 
if stored at 4 oC. It should be pre-warmed to 37 oC using a water bath prior to use on 314 
the cells to avoid cold shock. Water baths are a source of contamination in cell 315 
culture facilities and therefore should be regularly checked and cleaned, and an anti-316 
microbial agent added to the water.  317 
IMPORTANT NOTE: Maintenance and preparation of mammalian cell lines should 318 
be conducted in a class II biological safety cabinet and 70% ethanol used to sanitise 319 
all reagents and plastic ware used in the hood. All reagents must be prepared under 320 
aseptic conditions. 321 
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IMPORTANT NOTE: Like water baths, cell culture incubators represent another 322 
source of potential contamination. They too should be regularly checked, cleaned and 323 
a non-toxic anti-microbial added to the water tray. 324 
2. Trypsinise and seed cells at 4500 cells/well in a 96-well, flat-bottomed plate in 325 
triplicate (as a minimum for experimental replicates). Incubate cells overnight in cell culture 326 
incubator.  327 
 IMPORTANT POINT: Due to the edge effect on cell culture plates, conditions in the 328 
outer-most wells can lead to assay variability. We recommend not using the outer-329 
most wells and rather only add GM or PBS to them.  330 
For non-adherent, suspension cells, treated samples should be collected, spun down, 331 
resuspended in a fresh medium and treated with MTT solution.  332 
3.  Wash cells with PBS (enough to cover the monolayer) and add NPs at the desired 333 
concentration in GM at a volume of 150 μl/well. For the control wells add 150 μl/well of GM 334 
alone. Incubate cells for 72 hrs. 335 
 IMPORTANT NOTE: Careful pipetting technique must be used whilst washing, 336 
removing and adding GM to the cells. For adherent cells disturbance of the 337 
monolayer can dramatically affect the assay results. 338 
4. Following incubation with the NPs, remove the treatment media and wash the cells 339 
twice with PBS. Prepare fresh media of 50 μl of MTT (2 mg/ml) in d.H20, added to a total 340 
volume of 250 μl/well and incubate the plate for a further 4 hrs.  341 
 During this time the cells can be checked for the development of formazan crystals 342 
(formed through the reduction of tetrazolium salts), which appears as an intracellular 343 
purple precipitate. 344 
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5. Carefully remove the MTT solution to leave the insoluble formazan precipitate. Add 345 
200 μl of DMSO/well and 25 μl of Sorensen’s glycine buffer/well. Mix gently to resuspend 346 
the formazan crystals. 347 
 From this point onwards the experiment does not need to be conducted using aseptic 348 
technique. 349 
IMPORTANT NOTE: During mixing, avoid the production of air bubbles that could 350 
otherwise affect the optical absorbance readings. 351 
6. Remove the plate cover and measure the absorbance in each well at 570 nm 352 
wavelength using a microtitre plate reader for optical absorbance.  353 
7. Calculate the percentage cell viability as a ratio of mean absorbance from the 354 
replicates with respect to the control treatments, using the following formula: 355 
 % cell viability = (Isample/Icontrol)*100 [where I = absorbance intensity]. 356 
 357 
SUPPORT PROTOCOL 2 – TRYPAN BLUE EXCLUSION ASSAY 358 
As highlighted in Basic Protocol 2, >1 cytotoxicity assay should be employed to determine 359 
nanotoxicity in mammalian cells. Here we describe the use of trypan blue exclusion assay to 360 
support the findings from MTT analysis (see Basic Protocol 2). Trypan blue determines the 361 
number of live and dead cells depending of the principle that intact plasma membranes 362 
exclude the dye, whereas damaged/dead cells do not (Avelar-Freitas et al., 2014). 363 
Mammalian cells stocks are maintained and prepared using GLP as described above (basic 364 
protocol 2, point 1). 365 
 366 
Materials  367 
 368 
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Mammalian cell lines of choice (recommended a minimum of 3 should be used) 369 
 See basic protocol 1 for a detailed list of equipment and reagents required for growing 370 
 mammalian cell lines. 371 
 NP exposure solution (concentrations and nanomaterials tested are to be pre-372 
determined by the experimenter) 373 
 0.4% trypan blue solution (Sigma-Aldrich) 374 
 375 
1. Trypsinise and seed mammalian cells at 20000 cells/well in a 24-well, flat-bottomed 376 
plate in triplicate (as a minimum). Incubate cells overnight in a cell culture incubator. 377 
2. Gently wash cells with PBS (enough to cover the monolayer) and add NPs at the 378 
desired concentration in GM at a volume of 500 μl/well. For the control wells add 500 μl/well 379 
of GM alone. Incubate cells for 72 hrs. 380 
3. Following incubation with NPs, gently wash cells twice with PBS and use 100 μl/well 381 
trypsin/EDTA to detach cells from the well. Mix 10 μl of the cell suspension 1:1 with 0.4% 382 
trypan blue solution. Incubate for 2 min at room temperature.  383 
Trypan blue should be stored in a dark bottle at room temperature and filtered with a 384 
0.2 μM filter if used after prolonged storage. 385 
4. Count the unstained (viable) and stained (non-viable) cells. Calculate cell viability 386 
using the following equations:  387 
% cell viability = (unstained cells/total cells)*100  388 
% non-viable cells = (stained cells/total cells)*100 389 
 390 
SUPPORT PROTOCOL 3 – IMMUNOBLOTTING FOR APOPTOTIC MARKERS 391 
Immunoblotting (or Western blotting) is a molecular technique used to detect proteins in a 392 
complex milieu. Following extraction from cells, proteins are separated (usually by sodium 393 
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dodecyl sulphate-polyacrylamide gel electrophoresis; SDS-PAGE) and then immunoblotted 394 
by transferring the proteins to a solid substrate and proteins of interest detected using 395 
antibodies targeted against them. Here we describe a protocol using immunoblotting to assess 396 
apoptotic cell death in response to NP treatment. A variety of markers can be used to assay 397 
apoptosis, should reduced cell numbers be detected in Basic Protocol 2/Support Protocol V 398 
(e.g. cleaved Caspase [3,8 and 9], Puma, Noxa and p7056K). Here we describe the use of 399 
cleaved Poly (ADP-ribose) polymerase-1 (PARP1) as a read-out of apoptosis. During this 400 
type of cell death, Caspase/protease-mediated cleavage of PARP1 in fragments of 89/24kDa 401 
is a useful and easily detectable apoptotic hallmark (Kaufmann et al., 1993). The basic 402 
protocol is adapted from immunoblot protocols used in our previous work (Jenei et al., 2009; 403 
Webster et al., 2016). 404 
 405 
Materials  406 
 407 
Mammalian cell lines of choice (recommended a minimum of 3 should be used) 408 
 See basic protocol 1 for a detailed list of equipment and reagents required for growing 409 
 mammalian cell lines. 410 
 NP exposure solution (concentrations and nanomaterials tested are to be pre-411 
determined by the experimenter) 412 
 A cytotoxic agent that can be used as a positive control in the cell lines of choice (e.g. 413 
cisplatin; this agent and dose should be pre-determined for each cell line selected).  414 
PBS (see recipe); 0.1-0.5 L needs to be cooled to 4oC 415 
Protein extraction buffer (containing protease inhibitors; see recipe; cooled to 4oC) 416 
Plastic cell scrapers (Thermo Fisher Scientific) 417 
1.5 ml Eppendorf microcentrifuge tubes (Thermo Fisher Scientific) 418 
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Sonicator (Diagenode™ Bioruptor® Pico Ultrasonicator; Thermo Fisher Scientific) 419 
 -20oC freezer 420 
PierceTM BCA Protein Assay kit (Thermo Fisher Scientific) 421 
UV-Vis Spectrophotometer (Orion™ AquaMate 8000; Thermo Scientific) 422 
Dithiothreitol (DTT; Sigma-Aldrich) 423 
SDS (Sigma-Aldrich) 424 
Loading buffer (see recipe) 425 
Dry block heating system  426 
 Tris-HCl buffer (see recipe; Sigma-Aldrich) 427 
 40% acrylamide/bisacrylamide (Sigma-Aldrich) 428 
 Ammonium persulfate (APS; Sigma-Aldrich) 429 
>99.5% tetramethylethylenediamine (TEMED; Sigma-Aldrich) 430 
 Mini gel tank and associated casting plates, combs etc. (Mini-PROTEAN® Tetra 431 
Vertical Electrophoresis Cell ; Bio-Rad) 432 
Running buffer (10X; see recipe) 433 
 Protein Molecular Weight Standards (range = 6500-205,000 Daltons; Thermo Fisher 434 
Scientific) 435 
 Gel-loading tips (range 0.5–200 µL; Thermo Fisher Scientific) 436 
  Universal Power Supply (PowerPac™ ; Bio-Rad) 437 
 Polyvinylidene difluoride (PVDF) membrane (Thermo Fisher Scientific) or 438 
nitrocellulose  membrane (Thermo Fisher Scientific) 439 
Bent-tip stainless-steel forceps (Thermo Fisher Scientific) 440 
10X transfer buffer (see recipe) 441 
Sponge pad for blotting (Invitrogen) 442 
Tris-buffered saline/Tween20 (TBST; see recipe) 443 
Shaker plate/roller 444 
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Ponceau S solution (Sigma-Aldrich)  445 
Blocking solution (see recipe) 446 
Rabbit anti-PARP-1 antibody (sc-7150; Santa Cruz Biotechnology) 447 
Anti-rabbit Horseradish-peroxidase (HRP)-conjugated secondary antibody (#7074; 448 
Cell Signalling Technology) 449 
ECLTM Western blotting detection reagent (GE Healthcare) 450 
ChemiDocTM XRS+ system (Bio-Rad) 451 
Image analysis software (ChemiDoc Touch, Bio-Rad) 452 
Mouse anti-α-tubulin (DM1A; Cell Signalling Technology) 453 
Anti-mouse Horseradish-peroxidase (HRP)-conjugated secondary antibody (#7076, 454 
Cell Signalling Technology) 455 
 456 
Protein preparation from mammalian cells 457 
1. Trypsinise and seed mammalian cells at 1x106 cells/10 cm diameter petri dish (cell 458 
culture grade) and incubate cells overnight in a cell culture incubator. 459 
2. Gently wash cells with PBS (enough to cover the monolayer) and add NP/control 460 
treatments at the desired concentration in GM, at a volume of 5-10 ml/plate. Incubate cells 461 
for 72 hrs.  462 
A positive control (pro-apoptotic drug) treatment should be used to ensure the 463 
detection of apoptosis in the cell type of choice. 464 
3. Remove the GM and wash cells twice in ice-cold PBS (enough to cover the 465 
monolayer). Remove PBS and add 300 μl/plate ice-cold lysis buffer. Using a cell scraper 466 
(chilled to 4oC), scrape the cells off the dish then gently transfer the resulting lysate in a pre-467 
cooled microfuge tube.  468 
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IMPORTANT POINT: This step should be carried out on ice. From this step onwards 469 
keep all fractions and reagents used on ice throughout.  470 
4. Sonicate sample for 15-30 secs, typically 20 to 50 kHz. 471 
At this frequency, sonication ensures complete cell lysis and shears the DNA to 472 
reduce sample viscosity. 473 
5. Centrifuge lysate at 4oC for 20 min at 16000g. Gently aspirate the supernatant 474 
containing the protein extract and store in fresh cold tubes.  475 
At this point samples can be stored as aliquots at -20 oC. Avoid repeated freeze-476 
thawing as this can reduce sample integrity.  477 
6. Determine protein concentration using the PierceTM BCA Protein Assay kit (Thermo 478 
Fisher Scientific) according to the manufacturer’s protocol, or using a similar technique (e.g. 479 
the Bradford assay;(Bradford, 1976).  480 
Perform SDS-PAGE 481 
7. Prepare 10-25 μg of total protein by adding DTT at a final concentration of 0.1 M, 1% 482 
SDS in loading buffer (4X stock volume) to a total volume of 10-25 μl/sample. Denature 483 
samples at 90 oC for 10 min.  484 
DTT functions as a reducing agent to reduce disulphide bridges, whilst SDS functions 485 
as an anionic denaturing detergent. 486 
IMPORTANT NOTE: Wear gloves at all times when handling SDS-PAGE gels, as 487 
acrylamide is a potent, cumulative neurotoxin.  488 
8. Assemble the SDS-PAGE gel tank system and add 1 X running buffer to the top. 489 
Carefully load the protein in the desired sequence and load protein markers according to the 490 
manufacturer’s instructions.  491 
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Alternative gel tank systems are available from different manufacturers, so follow the 492 
assembly instructions for different apparatus accordingly.  493 
Prepare the gel the same day or the day before (storing overnight in running buffer at 494 
4 oC). Alternatively pre-cast gels can be purchased.  495 
Careful loading is critical to avoid sample spill over between adjacent gel lanes. We 496 
recommend using gel-loading tips to prevent this.  497 
9. Using gel electrophoresis, separate the proteins in a 12% SDS-PAGE resolving gel, 498 
overlaid with a 5% stacking gel (Table ii). Run protein separation at 90 V through the 499 
stacking gel and 120 V through the resolving gel.  500 
10. Once the proteins are fully resolved, dismantle the SDS-PAGE apparatus. Carefully 501 
remove the gels from the casting plates, remove the stacking gel and discard. Keep the 502 
resolving gel moist in transfer buffer, whilst preparing for immunoblotting.  503 
Perform immunoblotting 504 
11. Pre-soak a nitrocellulose transfer membrane in 1 X transfer buffer for 5 min. 505 
 If using a PVDF membrane, pre-soak in 100% methanol. 506 
 Membrane handling should be kept to a minimum and only use membrane  forceps 507 
when manipulating to reduce background staining. 508 
12. Prepare the transfer sandwich as previously described (Gallagher et al., 2008). 509 
Briefly, sandwich the gel and membrane between layers of pre-soaked filter paper/blotting 510 
sponges (in 1 X transfer buffer) in a transfer cassette, ensuring tight contact between the gel 511 
and membrane. For tank blotting, assemble the transfer sandwich in the gel tank and perform 512 
protein transfer in 1 X transfer buffer at 4 oC, ensuring the membrane faces the anode.  513 
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IMPORTANT POINT: Avoid air bubbles between the gel and membrane as this can 514 
lead to poor protein transfer. Using a clean pipette to roll over the membrane when 515 
assembling the transfer sandwich can easily remove bubbles.  516 
 Alternatively protein transfer can be done using semi-dry blotting apparatus. These 517 
 systems should be used according to the manufacturer’s instructions.  518 
13. Once protein transfer is complete, carefully dismantle the transfer sandwich. Wash the 519 
membrane twice in 1 X TBST (enough to cover the membrane) for 5 min on a shaker 520 
plate/roller.  521 
14. Stain the membrane with Ponceau S solution (enough to cover the membrane) for 1 522 
min, to visualise proteins and ensure complete transfer (protein bands will stain red). Then 523 
wash the stain away with d.H20 several times with agitation until all the Ponceau S solution is 524 
removed from the membrane. 525 
15. Block the membrane for 1-2 h at room temperature with agitation in blocking solution 526 
(containing 5% milk; enough to cover the membrane).  527 
 5% BSA can also be used as a blocking reagent and for alternative antibodies to the 528 
ones suggested here, should be used as recommended for individual antibody clones. 529 
16. Dilute the anti-PARP-1 antibody in enough blocking solution to cover the membrane 530 
and incubate with the membrane overnight at 4 oC with constant gentle agitation.  531 
 We standardly use a 1:200 dilution, but this will require optimisation for individual 532 
cell types to determine the optimal antibody/protein ratio.  533 
17. Wash the membrane three times in 1 X TBST for 10 min each at room temperature 534 
with constant agitation.  535 
 This step is important to remove any unbound antibody. 536 
18. Add the cognate secondary antibody diluted in blocking solution for 1 h at room 537 
temperature with gentle agitation. 538 
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 Use the secondary antibody at a minimal dilution of 1:2500, although this will 539 
require optimisation for the cell types used.  540 
19. Repeat step 17. Incubate the membrane with ECL reagent (according to the 541 
manufacturer’s instructions) and detect the chemiluminescent signal using the desired 542 
imaging system (e.g. the ChemiDocTM XRS+ system; Bio-Rad). Use image analysis software 543 
to analyse protein band intensity.  544 
 X-ray film (with/without automated developing) is also a commonly used method for 545 
signal detection.  546 
20. Rinse membrane in methanol and then repeat step 17. Dilute the anti-α-tubulin 547 
antibody in enough blocking solution to cover the membrane and incubate with the 548 
membrane overnight at 4 oC with constant gentle agitation.   549 
Detection of α-tubulin in the cells is used as a loading control. The choice of a 550 
loading control can be modified depending on the cell type used and the size of the 551 
protein(s) of interest being detected by immunoblotting. 552 
21. Repeat steps 17-19.   553 
 Determining the ratio between the cleaved PARP-1 (89 kDa) and full-length PARP-1 554 
(116 kDa) bands relative to the gel loading control, can be used as a readout for 555 
caspase-mediated apoptosis.   556 
  557 
BASIC PROTOCOL 3 – X. LAEVIS PHENOTYPIC ABNORMALITY ASSAY FOR 558 
NANOTOXICITY ASSESSMENT 559 
This protocol is designed to be used in parallel with cell-based cytotoxicity assays as part of 560 
an integrated toxicity assessment in order to obtain a complete safety profile of a novel NP 561 
(Fig. i). X. laevis is an ideal model organism to be used for comparatively high-throughput 562 
screening (Tomlinson et al., 2009) and has been used as a toxicity model in the frog 563 
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teratogenesis assay-Xenopus (or FETAX assay) for drugs in their early stages of drug safety 564 
evaluation (Leconte and Mouche, 2013). This is largely due to X. laevis being a relatively 565 
inexpensive and rapid model that that can be easily scaled-up as a large number of embryos 566 
can be produced. X. laevis embryos develop externally, making them an easily accessible 567 
system for exposure to NPs. Previous work has shown that this methodology allows both 568 
external NP exposure and internal exposure to key internal organs for assessing potential 569 
toxicity (Webster et al., 2016). Briefly, X. laevis embryos are exposed to a NP-containing 570 
incubation solution over a desired developmental period that can be adapted depending on the 571 
specific aims of the nanotoxicity assessment protocol.  572 
 573 
Materials  574 
 575 
Nieuwkoop and Faber (NF) stage 1 X. laevis embryos (see Support Protocol 4)  576 
MMR solution (see recipe) 577 
Pasteur pipette (we recommend glass. Whole embryos are too large to fit into a 578 
standard pipette, therefore mark the end with a diamond pen, break off 579 
cleanly and fire the end briefly to melt any sharp edges. Alternatively, if 580 
desired, plastic Pasteur pipettes can be used with the end removed) 581 
10 cm2 Petri dish (Fisher Scientific) 582 
Culture incubator (set to desired temperature; see below for details) 583 
Stereomicroscope with two-armed fibre optic illuminator to allow the angle of 584 
illumination to be easily adjusted 585 
Dumont #5 forceps (stainless steel; Sigma-Aldrich). These are ultrafine and can be 586 
used for carefully manipulating embryos throughout the described protocol. 587 
24-well culture plate (non-cell culture grade; Fisher Scientific) 588 
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NP exposure solution (concentrations and nanomaterials tested are to be pre-589 
determined by the experimenter) 590 
Ethyl 3-aminobenzoate methanesulfonate (0.6 mg/ml; Fluka) 591 
MEMFA fixative (see recipe) 592 
Phosphate-buffered Saline (PBS) and PBST (see recipes) 593 
3 cm2 Petri dish (Fisher Scientific) 594 
Agarose gel (2% [w/v]; Sigma-Aldrich; see recipe) 595 
Long-handled scalpel (10A blades) 596 
Light microscope with charge coupled-device (CCD) digital camera for whole-mount 597 
imaging of embryos 598 
Methanol (analytical grade; Sigma-Aldrich), 25%, 50%, 75%, 100% [v/w] in PBS 599 
Glass vials with screw caps (3.5 ml; SGL) 600 
Parafilm MTM wrapping film (Fisher Scientific) 601 
-20 oC freezer 602 
 603 
1. Harvest NF stage 1 X. laevis embryos (see Support Protocol 4) and incubate between 604 
12–23oC until at required developmental stage (Fig. iii). During the incubation times it is 605 
important to regularly observe the embryos (at least twice daily or more at early stages) 606 
to remove any dead embryos and ensure the correct NF stage has been reached. 607 
Developmental times of embryos are dependent on incubation temperature and 608 
culturing them at differing temperatures can speed or slow development. Typically, 609 
after incubation at 23oC, embryos are NF stage 4 after ~ 2 h, NF stage 15 after ~ 17 610 
h, and NF stage 38 after incubation for ~ 2 days 5 h.  611 
IMPORTANT NOTE: Bacteria grow well at the higher incubation temperatures so 612 
embryos cultured between 18-25 oC should be regularly monitored and washed twice 613 
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daily. To avoid this problem, the 0.1X MMR culture media of later stage embryos 614 
(NF stage 23 onwards) can be supplemented with 25 μg/ml of gentamicin. 615 
2. In a 24-well plate, add 200 µl of NPs in 0.1 X MMR solution to each well at a 616 
concentration that is 10 X higher than that of the desired final concentration. For the 617 
control wells, add 200 µl 0.1 X MMR alone. 618 
3. At the required NF stage, select 5 healthy embryos and transfer using a volume of 619 
1800 µl 0.1 X MMR using a glass Pasteur pipette into one well of a 24-well plate. Repeat 620 
until the wells for each of the desired NP concentrations (along with the control wells) 621 
contain 5 embryos to a final volume of 2 ml. Incubate at the same temperature that the 622 
embryos were initially developed at.  623 
4. Continue to incubate X. laevis embryos until they have reached the desired end stage 624 
(Fig. iii).  625 
Again it is important that the embryos are checked several times a day to identify 626 
any dead ones and to assess developmental progress. Dead embryos should be 627 
removed from the well during this incubation period and the number of dead 628 
recorded. 629 
5. Make a note of any dead X. laevis embryos at the end of the incubation time. Wash 630 
embryos with 0.1 X MMR and using a Pasteur pipette, gently transfer to a new 24-well 631 
plate containing 1 ml of 0.6 mg/ml ethyl 3-aminobenzoate methanesulfonate salt to 632 
anesthetise the embryos. Incubate for 20 min at room temperature to ensure embryos are 633 
fully anesthetised prior to fixing (Sherwood et al., 2008; Webster et al., 2016). 634 
A variety of nanomaterials are synthesised for use as fluorescent bioimaging tools 635 
(Wolfbeis, 2015). If such fluorescent NPs are being tested using this protocol (e.g. 636 
metal chalcogenide quantum dots [QDs]) they can be detected in the embryos 637 
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using live whole-mount fluorescent imaging at this stage in the protocol (Webster 638 
et al., 2016); see support protocol 5).  639 
6. Wash away the anaesthetic solution with several rinses of 0.1 X MMR before fixing 640 
the embryos with MEMFA for 1 h at room temperature or overnight at 4oC. 641 
IMPORTANT NOTE: Fresh MEMFA should be prepared for each experiment. 642 
If the embryos are going to be used for transmission electron microscopy (TEM; 643 
which can be used to determine exposure to non-fluorescent NPs) then MEMFA 644 
should not be used for embryo fixation. Rather an alternative fixing protocol 645 
provides improved ultrastructural analysis of X. laevis embryos by TEM (see 646 
alternate protocol 1). 647 
7. Following fixation, aspirate off as much MEMFA as possible and wash embryos 648 
twice with excess PBST.  649 
8. Whole-mount images of the embryos should now be taken to assist with phenotypic 650 
scoring. To do this, prepare a 2% (w/v) agarose gel by heating 100 mg agarose in 5 ml 651 
PBS until all the agarose has dissolved. Then pour the 2% agarose into the bottom of a 652 
10 cm3 culture dish and leave to cool and set (should take approximately 30 minutes). 653 
Agarose gel-containing imaging wells (as described above) can be prepared in 654 
advance of the experiment and stored at 4 oC prior to use.  655 
Once set, a small indentation/notch can be made in the agarose gel using a scalpel 656 
to help position the embryos for imaging.  657 
9. Pour a small layer of PBS over the agarose gel. Gently transfer the X. laevis embryos 658 
into the agarose gel-containing dish using a Pasteur pipette and use this as a platform for 659 
imaging.  660 
The PBS should cover the embryos so that they remain hydrated, but not be in excess 661 
such that it is difficult to retain the embryos in the desired position for imaging.  662 
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10. Observe each embryo using a light microscope and rank for phenotypic abnormalities 663 
(Table iii). Calculate phenotypic abnormality; the number of malformed larvae as a 664 
percentage of the total number at the beginning of the experiment. Likewise percentage 665 
mortality should be calculated in the same way. 666 
Common abnormalities induced by NP exposure include loss of melanocytes, 667 
blistering, edema, tail loss, bent spine, degradation of tissue, developmental delay, 668 
eye deformities, and stunted growth (Webster et al., 2016); Table iii).  669 
Exposure should be confirmed of NPs that do not produce notable nanotoxicity as 670 
scored in this phenotypic abnormality assay. If the NP is fluorescent this can be done 671 
as described in point 5 (see support protocol 5), but if not we propose that 672 
transmission electron microscopy (TEM) imaging of X. laevis tissue will facilitate 673 
confirmation of NP uptake in the embryos (see alternate protocol 1).  674 
11. Following scoring, dehydrate the embryos for long-term storage. To do this, transfer 675 
the embryos into glass vials using a Pasteur pipette. Gently aspirate the PBST and 676 
replace with 25% methanol in PBS for 5 min, completely immersing all embryos in the 677 
glass vial.   678 
12. Then aspirate the 25% methanol and immerse the embryos in 50% methanol. Repeat 679 
this step with 75% methanol and finally 100% (with 5 min between each concentration). 680 
If required, embryos can be rehydrated for further analysis by reversing steps 12 and 681 
11.  682 
13. After dehydration, X. laevis embryos can be stored long term in 100% methanol at -683 
20oC. Finally, seal the glass vial cap with Parafilm for long-term storage at -20oC. 684 
 685 
SUPPORT PROTOCOL 4 – HARVESTING X. LAEVIS EMBRYOS 686 
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X. laevis have been used as model organisms for biological research for decades, particularly 687 
as developmental vertebrate systems. As a result, detailed methodologies have been devised 688 
to obtain and work with X. laevis embryos (Sive et al., 2000). Ethical legislation and 689 
considerations must be in place when working with adult X. laevis frogs, the specific 690 
requirements of which will be dependent upon geographical and institutional location. This is 691 
not only a legal requirement in many countries, but such ethical considerations will also assist 692 
with maintaining a well cared for population of adult frogs for generating healthy embryos. 693 
You will need access to an aquarium facility for holding X. laevis colonies, where males and 694 
females should be housed in separate tanks. The following protocol describes the steps 695 
required to collect eggs and conduct fertilisations in order to obtain X. laevis embryos for 696 




Female X. laevis adults (2 or more) 701 
Pregnant mare serum gonadotrophin (PMSG; Intervet) 702 
25-gauge (25G; BD Biosciences) needle and 1 ml syringe (Fisher Scientific) 703 
Non-textured, powder-free gloves (Fisher Scientific) 704 
Human chorionic gonadotrophin (hCG; Intervet) 705 
Culture incubator (set to 17oC) 706 
10 cm2 Petri dish (Fisher Scientific) 707 
MMR (see recipe) 708 
1 male X. laevis adult 709 
0.05% Ethyl 3-aminobenzoate methane sulfonate (Fluka) 710 
Surgical equipment including scalpels, forceps and curved scissors 711 
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Testis buffer (see recipe) 712 
-20oC freezer 713 
d.H2O  714 
Cysteine de-jellying solution (see recipe) 715 
Glass beaker  716 
 717 
1. Prime female X. laevis with an injection of 100 units of PMSG into the dorsal lymph 718 
sac 5–7 days before requiring embryos.  719 
We recommend priming and inducing ovulation in >1 female, in case egg yield and 720 
quality is not good, as this can vary greatly between individual animals. 721 
2. Isolate testes from an adult male X. laevis by first anesthetising him by submersion in 722 
0.05% Ethyl 3-aminobenzoate methanesulfonate for a minimum of two hours. Remove 723 
the testes by exposing the abdominal cavity and drawing out the fat body with forceps. 724 
The testes lie at the base of the fat body and can be identified as white, oval shaped 725 
organs covered in a fine network of capillaries. Remove both testes and store in testes 726 
buffer at 4 oC for up to 14 days post-isolation. 727 
IMPORTANT NOTE: The male should be dead due to the overdose of anaesthetic. 728 
Confirm no reaction by pinching the toes before starting the surgery. Snip the heart 729 
prior to-, and freeze the sacrificed male, post- isolation of the testes.  730 
3. Induce ovulation by injection of 250 units hCG into each of the dorsal lymph sacs 731 
(500 units total) using a 25G needle. Incubate induced females at 17oC. 732 
The dorsal lymph sac is located directly rostral to the hind limbs. It can be located 733 
between the lateral line that appears as ‘stich’ marks on the adult’s skin and the 734 
spine.  735 
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IMPORTANT NOTE: The skin covering the dorsal lymph sac is loose and therefore 736 
it is straightforward to insert the needle subcutaneously and inject the hCG, however 737 
it is crucial not to penetrate too deeply into the muscle.  738 
4. After 12-14 h the females should be ready to lay, which can be seen as the cloaca will 739 
appear red and swollen (due to the oocytes collecting in a sac close to this region). 740 
Gently ‘squeeze’ the abdomen of the female X. laevis to encourage egg release into a 10 741 
cm2 Petri dish containing 0.1 X MMR (enough to cover the eggs). This is done by very 742 
gently applying lateral/vertical pressure to the lower abdomen.  743 
IMPORTANT NOTE: Eggs should be fertilised immediately when collected in this 744 
manner. From this point onwards in the protocol it is critical to progress as rapidly 745 
as possible through the remaining steps, this helps ensure quality of the resulting 746 
embryos. 747 
As an alternative to ‘squeezing’, eggs can be collected passively by allowing females 748 
to lay in 1X MMR, where eggs will be viable for fertilisation for up to 8 h post-laying.   749 
5. Fertilise the harvested eggs by cutting off a small piece of one testis (<25%) and 750 
homogenise the testis section using a scalpel blade and forceps. Add 1ml 1X MMR to the 751 
mashed up testis piece. Mix the testis slurry well with the eggs across the entire dish to 752 
promote fertilisation. Leave for 5 minutes then flood the dish with 0.1X MMR and leave 753 
for 20-30 minutes. 754 
6. Incubate the eggs at 17 oC and monitor regularly for successful fertilisation. The first 755 
sign is a cortical contraction of the animal pole approximately 5 min post-fertilisation. 756 
However, by 15-30 min fertilised eggs will reorient such that the animal pole faces up, 757 
which is the most reliable sign that fertilisation has been successful. 758 
The release of cortical granules into the space between the fertilised egg and the 759 
vitelline membrane blocks polyspermy and causes the eggs to turn with their 760 
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membranes according to gravity, with their pigmented animal poles facing up. At this 761 
point fertilised eggs will be much firmer than unfertilised ones, so it is easy to tell if 762 
the fertilisation has been successful or not by 30 min post-fertilisation.  763 
7. Continue to incubate the fertilised eggs at 17 oC for another 1-2 h. Upon entering the 764 
first cell cycle, cortical rotation occurs, which is required for formation of dorsal tissues 765 
and usually occurs within 2 h of fertilisation at 17 oC. 766 
IMPORTANT NOTE: Do not disturb the embryos during this incubation period too 767 
much as it can interfere with correct dorso-ventral patterning. For example, shaking 768 
the embryos during this time is known to produce spontaneous secondary axis 769 
formation through microtubule reorientation.  770 
8. X. laevis embryos are surrounded by a thick layer of protective jelly that must be 771 
removed prior to further experimentation. Ideally this should be done after cortical 772 
rotation to reduce the likelihood of developmental defects (see point 7). In a glass beaker, 773 
gently swirl the embryos in 2% cysteine (w/v) de-jellying solution until they pack closely 774 
together.  775 
The time required for this step can vary depending on differences between embryo 776 
batches, however it should normally take around 5 min and no longer than 10 min. 777 
IMPORTANT NOTE: The de-jellying solution needs to be made fresh on the day of 778 
use and used at room temperature. 779 
IMPORTANT NOTE: Do not over-treat as this can lead to developmental defects 780 
and can contribute to poor embryo quality.  781 
9. Remove cysteine solution and wash the eggs several times with distilled water (>5 782 
washes) followed by several washes with 0.1 x MMR. Embryos are then reared in 0.1 X 783 
MMR, ready for further experimental procedures. 784 
 785 
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SUPPORT PROTOCOL 5 – WHOLE-MOUNT IMAGING OF X. LAEVIS EMBRYOS 786 
FOR FLOUORESCENT NP UPTAKE  787 
This protocol can be used to investigate internalisation of fluorescent NPs in X. laevis 788 
embryos. We have previously demonstrated that this protocol works well using 20 nm 789 
fluorescent carboxylate-modified NPs (PS-COOH; Molecular Probes FluoSphere beads®; 790 
Thermo Fisher Scientific®; catalog #F8887), thus we propose that these NPs offer a useful 791 
positive control for NF stage 45 embryos, exposed to 1015 NP/ml from NF stage 38 (Webster 792 




3 cm2 Petri dish (Fisher Scientific) 797 
Agarose gel (2% [w/v]; Sigma-Aldrich; see recipe) 798 
Long-handled scalpel (10A blades) 799 
Tadpole stage X. laevis embryos (from NF stage 38 onwards; see Fig. iii), 800 
anesthetised and pre-exposed to florescent NPs (see point 5, Basic Protocol 3 801 
for details). As described above, 20 nm PS-COOH NPs should be used as a 802 
positive control. 803 
Glass Pasteur pipette (prepared as described in Basic Protocol 3) 804 
Dumont #5 forceps (stainless steel; Sigma-Aldrich). These are ultrafine and can be 805 
used for carefully manipulating embryos throughout the described protocol. 806 
PBS (see recipe) 807 
Fluorescent microscope with CCD digital camera 808 
 809 
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1. Prepare agarose imaging plates for whole-mount X. laevis embryos as described in 810 
point 8, Basic Protocol 3.  811 
2. Pour a small layer of PBS over the agarose gel and gently transfer the X. laevis 812 
embryos into the agarose gel-containing imaging plate (see point 9, Basic Protocol 3 for 813 
details).  814 
3. Image the embryos using a fluorescent microscope according to the emission filter 815 
required to excite the NPs being tested.  816 
For the PS-COOH NPs, an emission filter of 509-547 nm should be used. The 817 
fluorescence from these NPs will appear bright throughout the embryo (Webster et 818 
al., 2016). 819 
4. Time-lapse images (with time-frame stills of 0.7 seconds) can be used to monitor 820 
fluorescent NPs traveling through the vasculature of the X. leavis embryos, which is 821 
particularly clear in the embryonic intersomitic blood vessels (Webster et al., 2016). 822 
 823 
ALTERNATE PROTOCOL 1 – TEM IMAGING OF X. LAEVIS EMBRYO 824 
SECTIONS FOR NP UPTAKE  825 
Support protocol 5 cannot be used to confirm uptake of non-fluorescent NPs in X. laevis 826 
embryos and for this reason such NPs require an alternative procedure to ensure embryo 827 
exposure to these nanomaterials. Electron microscopic techniques facilitate high-resolution 828 
visualization of NPs in tissues and in particular TEM has been used for a long-time in NP 829 
research. Due to the complexity of sample preparation, imaging and interpretation of 830 
ultrastructual NP localisation within tissues, and that the infrastructure required for TEM 831 
analysis is often housed in centralised facilities, where possible it is pertinent to seek advice 832 
about TEM experimental design with expert staff within such core facilities. This will assist 833 
with optimisation of advanced TEM imaging for specific nanomaterials, but here we describe 834 
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a protocol that is suitable for preparing high-quality X. laevis embryo sections that is suitable 835 
at least for imaging iron oxide core NPs (Webster et al., 2016). The processes of fixing, 836 
embedding and sectioning X. laevis embryos for TEM is based on a previously described 837 
method developed for imaging carbon NPs in vivo (Bacchetta et al., 2012).  838 
 839 
Materials  840 
 841 
Tadpole stage X. laevis embryos (from NF stage 38 onwards; see Fig. iii), 842 
anesthetised and pre-exposed to NPs (see point 5, Basic Protocol 3 for details).  843 
Glass Pasteur pipette (prepared as described in Basic Protocol 3) 844 
MMR (see recipe) 845 
TEM fixing buffer (see recipe) 846 
Osmium tetroxide (OsO4; Sigma-Aldrich), 1% [v/w] in PBS 847 
Methanol (analytical grade; Sigma-Aldrich), 25%, 50%, 75%, 100% [v/w] in PBS 848 
Propylene oxide resin (TAAB Laboratories Equipment Ltd.) 849 
Incubator (set to 60 oC) 850 
Microtome (Reichert Ultracut E) 851 
Carbon-coated 300 μM mesh copper grids (Agar Scientific) 852 
TEM instrument with imaging modality 853 
 854 
1. Immerse X. laevis embryos in 0.6 mg/ml ethyl 3-aminobenzoate methanesulfonate salt 855 
for 20 min at room temperature to anesthetise.  856 
2. Wash away the anaesthetic solution with several rinses of 0.1 X MMR and fix the 857 
embryos in TEM fixing buffer (enough to immerse the embryos) for 1 h at room temperature. 858 
During this time replace the TEM fix twice with fresh buffer. 859 
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3. Post-fix the embryos in 1% OsO4 for 1.5 h at 4 oC. 860 
This step is needed to increase the electron density in lipids and proteins. 861 
4. Dehydrate the fixed embryos in a decreasing concentration of methanol, as described 862 
for point 12 of basic protocol 3. 863 
5. Once dehydrated, wash the embryos in 75% propylene oxide resin and leave in 100% 864 
pure resin overnight. 865 
6. Submerse embryos in fresh resin and then polymerise at 60 oC for 48 h. 866 
7. Using a microtome, cut semi-thin 1 μm sections of the embryos.  867 
Cut in an anterior to posterior direction to produce transverse sections along the 868 
entire embryo. Analyse all tissues across the anterior-posterior axis as the location of 869 
the NPs will depend upon the biodistribution of specific nanomaterials within X. 870 
laevis embryos. 871 
Ultrathin sections (~50 nm) can also be used if required for NP detection.  872 
8. Mount the sections in onto carbon-coated 300 μm mesh copper grids. 873 
9. Image sections using a TEM according to the settings required for the instrument. 874 
As an example, we have successfully used a TecnaiTM 20 TEM (FEI; Thermo Fisher 875 
Scientific) with AMT cameras, operating at an acceleration voltage of 200 kV to 876 
image iron oxide core NPs (Webster et al., 2016). Likewise carbon NPs have been 877 
successfully imaged in X. laevis embryos using a Zeiss LEO 912ab Energy Filtering 878 
TEM at 80 kV (Bacchetta et al., 2012). 879 
 880 
REAGENTS AND SOLUTIONS  881 
General laboratory reagents are supplied by Sigma-Aldrich.  Use d.H20 in the following 882 
recipes (unless otherwise stated): 883 
 884 
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Agarose gel 885 
 100 mg agarose  886 
 5 ml PBS 887 
 888 
Blocking solution  889 
5 g BSA 890 
100 ml 1 TBST 891 
     892 
Blocking Buffer: 893 
7.5 g nonfat dry milk 894 
15 ml 10X TBS 895 
0.15 ml Tween-20 (100%) 896 
 Final volume 150 ml 897 
 898 
Cysteine solution  899 
3 g cysteine  900 
100 ml 0.1 x MMR 901 
 Adjust to pH 7.8 with 10 M NaOH 902 
 903 
4X Loading buffer  904 
3 mL of 1 M DTT  905 
1.5 mL of 1 M pH 6.8 Tris-HCl  906 
0.6 g of SDS  907 
2.4 mL of glycerol 908 
0.03 g of bromophenol blue 909 
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 Final volume to 7.5 ml. Store at -20°C 910 
 911 
Lysis buffer 912 
50 mM Tris-HCl 913 
1% Triton X-100 914 
150 mM NaCl 915 
 Final volume to 200 ml in PBS. Adjust pH to 7.4. 916 
 917 
MMR 918 
100 mM NaCl 919 
2 mM KCl 920 
1 mM MgCl2 921 
2 mM CaCl2 922 
5 mM HEPES (pH 7.6) 923 
 Adjust to pH 7.4. 924 
 925 
MEMFA 926 
i) 10 X MEM salts (autoclave and store in the dark) 927 
1 M MOPS 928 
20 mM EGTA 929 
10 mM MgSO4 930 
5 mM HEPES (pH 7.6) 931 
 Adjust to pH 7.4 with NaOH pellets. Dilute in d.H2O for a 1 X working 932 
 solution. 933 
i) 1 X MEMFA  934 
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3.7% formaldehyde 935 
1 X MEM salts 936 
 937 
PBS/PBST 938 
 i) 10 X PBS  939 
1.4 M NaCl 940 
26.8 mM KCl 941 
100 mM Na2HPO4 942 
17.6 mM KH2PO4 943 
       Adjust to pH 7.4 with HCl. Dilute in d.H2O for a 1 X working solution 944 
ii) 1 X PBST  945 
0.1% Tween-20 946 
1 X PBS 947 
 948 
Ponceau stain 949 
0.2 g Ponceau S 950 
5 ml glacial acetic acid  951 
 Final volume to 100 ml  952 
 953 
10 X Running buffer 954 
30.2 g Tris-base (25 mM)  955 
144 g Glycine (190 mM) 956 
 0.1% SDS 957 
 Final volume to 1 L. Adjust to pH 8.3 958 
 959 
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Sorensen’s glycine buffer 960 
121 g Tris Base 961 
 28.55 ml Acetic Acid 962 
 50 ml, 0.5 M EDTA 963 
 Final volume to 500 ml. Adjust to pH 8.0  964 
 965 
TBST 966 
24.23 g Tris-HCl  967 
80.6 g NaCl 968 
0.1% Tween-20 969 
 Final volume to 1 L. Adjust to pH 7.6. Dilute in d.H2O for a 1 X working 970 
solution. Add 0.1% Tween-20.  971 
 972 
TEM fixing buffer 973 
4% paraformaldehyde 974 
2% glutaraldehyde 975 
0.1M sodium cacodylate buffer (4.28 g sodium cacodylate in 200 ml d.H2O) 976 
 Adjust to pH 7.4 977 
 978 
Testis buffer (in 1 X MMR) 979 
80% Foetal Calf Serum 980 
50 μg/ml gentamycin-sulfate 981 
 982 
10 X Transfer buffer 983 
30.2 g Tris-base (25 mM),  984 
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144 g Glycine (190 mM)  985 
0.1% SDS 986 
 Volume to 1 L. Adjust to pH 8.3 987 
 988 
10 X Tris-HCl buffer 989 
61 g Trizma Base  990 
  Volume to 1 L. Adjust to pH 7.6 using HCl 991 
 992 
COMMENTARY  993 
  994 
Background Information 995 
Here we have described the use of non-specialist cytotoxicity testing protocols in 996 
combination with a X. laevis embryonic phenotypic assay for nanotoxicity assessment. 997 
Specifically, testing well characterised nanomaterials at the physico-chemical level (Basic 998 
protocol 1) with standard cytotoxicity assessment (Basic protocol 2) and using this in 999 
combination with the X. laevis embryonic phenotypic assay (Basic protocol 3), can bridge the 1000 
gap between conventional in vitro (cell culture models) and in vivo (mammalian systems) 1001 
nanotoxicity assessment (Webster et al., 2016). We have shown that direct comparison of the 1002 
cytotoxicity and X. laevis data can provided a logical ranking system to generate an overall 1003 
hazard score for NPs (Webster et al., 2016). Briefly, a simple scoring system ranging from 0-1004 
2 can distinguish hazard score, where NPs score 0 when the percentage of cell viability and 1005 
healthy X. laevis embryos is >76%, 1 when this percentage ranges from 50-75% and 2 when 1006 
it is <50%. From these criteria only NPs that score 0 in all nanotoxicity assessment protocols 1007 
should progress to further toxicity assessment in mammalian models (Fig. i). This approach 1008 
can reduce false negatives that could otherwise be generated from cell-based assays used in 1009 
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isolation. Thus, only NPs that produce no-to-low toxicity assessment in the described 1010 
protocol progress to further evaluation in mammalian systems, thereby reducing investment 1011 
in time and money spent on more costly rodent models, which is important given the year on 1012 
year increase in development of nanotherapeutics. Overall, this protocol provides biomedical 1013 
researchers with nanotoxicity assessment at early stage in nanotherapeutic design to quickly 1014 
and easily identify nanomaterials that require additional modifications for improved safety, 1015 
prior to mammalian testing (Fig. i).  1016 
 1017 
Critical Parameters and Troubleshooting 1018 
There are several critical parameters that will affect successful outcome of the described 1019 
protocol and therefore must be considered by users. These parameters include the following: 1020 
 1021 
Dosing and storage of NPs.  1022 
 The most suitable conditions of NP storage depend on the type of material from which 1023 
the NPs are composed of. It is not possible to state general conditions. The chosen medium 1024 
should guarantee stability of the NPs over time. If the material is not sensitive to low 1025 
temperature it is suggested to store stock solutions in the fridge, mostly if they contain 1026 
organic/biological moieties to avoid degradation. Before making any measurements it is also 1027 
necessary to check the stock solution in terms of homogeneity in order to guarantee the right 1028 
evaluation of the dose. Often, NP dispersions can be affected by flocculation over time, if 1029 
flocculation is reversible, this process does not represent a problem. It is only necessary to re-1030 
disperse the sediment in the dispersion through simple shaking and/or 5-10’ sonication of the 1031 
NP dispersion before the measurement or preparation of the samples.   1032 
 1033 
Cell culture considerations  1034 
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 There are several important considerations when conducting cytotoxicity analysis for 1035 
NP testing. The first is to select cell types (3 or more) that best model the exposure route(s) 1036 
and target organ(s) of the nanomaterial of interest. Next, the appropriate methodology must 1037 
be selected that can accurately assess cytotoxicity of the NP of interest without the 1038 
development of false-negatives/-positives, which is important to carefully consider because 1039 
not all nanomaterials are compatible with commonly employed methods. For example, MTT 1040 
(the method described here; Basic protocol 2) although being easy, quick and readily 1041 
affordable, is not compatible with several types of NPs. Wang Yu and Wickliffe, 2011 1042 
indicated that titanium oxide nanoparticle (nano-TiO2) induces superoxide formation in 1043 
mammalian cells that reduces tetrazolium salts and produces the absorbant formazan end 1044 
products (Wang et al., 2011). Monteiro-Riviere, Inman and Zhang, 2009 showed that single-1045 
walled carbon nanotubes SWCNT and carbon black CB alone (absence of cells) interact with 1046 
the MTT to cleave the tetrazolium ring and lead to a false positive reaction (Monteiro-Riviere 1047 
et al., 2009). Whilst Belyanskaya et al., 2007 found that sodium dodecyl sulfate-suspended 1048 
SWCNTs interfere more with MTT assay than polyoxyethylene sorbitan monooleate-1049 
suspended SWCNTs (Belyanskaya et al., 2007). Table i lists which types of NP-based 1050 
materials have previously been demonstrated to be compatible with commonly employed 1051 
cytotoxicity assays. Finally, it is essential to use GLP when conducting in vitro cell work; 1052 
including cell line validation, equipment validation/maintenance, mycoplasma contamination 1053 
testing, employment of strict aseptic technique and using low-passage cell culture are all 1054 
critical in obtaining high-quality, reproducible cytotoxicity data.  1055 
 1056 
Immunoblotting considerations   1057 
 Immunoblotting is a simple molecular procedure for the quantitative detection of 1058 
proteins in cells/tissues. Here we describe a protocol to detect apoptotic markers in response 1059 
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to NP-induced cytotoxicity (Support protocol 3). Despite its simplicity, an array of problems 1060 
can be encountered that require troubleshooting to prevent unexpected results and a 1061 
comprehensive description of effective immunoblotting troubleshooting has previously been 1062 
provided (Mahmood and Yang, 2012). Briefly, use fresh protein sample using lysis buffer 1063 
containing phosphatase inhibitors to prevent sample degradation and ensure the transfer 1064 
sandwich is effectively prepared by avoiding air bubbles between the gel, and membrane. A 1065 
final crucial consideration for immunoblotting is effective optimisation of antibody 1066 
concentration for specific samples, as too low and the signal will not be visible and too high 1067 
could result in over-exposed (negative) bands on the blot, and high background signal. 1068 
Altering membrane-washing times, the blocking reagent used and membrane exposure times 1069 
can also dramatically affect signal-to-noise ratio, and therefore can also require optimisation.  1070 
 1071 
X. laevis egg quality 1072 
 A major critical parameter for nanotoxicity assessment in X. laevis embryos is the 1073 
quantity and quality of egg production (and thus the zygotes generated from these), which has 1074 
a major influence on the collection of reliable data. The Xenopus research community are 1075 
aware that egg quality and production levels are variable, which is often attributed to 1076 
differences between individual females. Therefore, experimental replication can be improved 1077 
by acquiring eggs from consistently good producers. Acceptable methods for identification of 1078 
individuals include tagging (with beads or microchips), tattooing, branding, monitoring of 1079 
dorsal markings in pigmented frogs and perhaps more simply (if space is available), housing 1080 
individuals in designated tanks. Implementing the following basic policies will increase the 1081 
chances of quality egg harvests:  1082 
i) Comprehensive training of personnel preforming the procedures. 1083 
ii) Introducing a robust system for identifying individual animals. 1084 
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iii) Ensuring a compulsory rest period of at least 4 months between ovulations (Green 1085 
et al., 2007). This will allow females to be reused for several years provided they 1086 
remain healthy. 1087 
iv) Daily monitoring of post-procedure females for up to two weeks in a separate 1088 
recovery tank, to ensure there are no complications caused by ovarian hyper- 1089 
stimulation (Green et al., 2007). 1090 
v) Detailed record keeping of all procedures conducted. 1091 
vi) Strict quarantine procedures for incoming animals into the aquarium. 1092 
 There is also awareness in the community that X. laevis husbandry can also greatly 1093 
influence egg quality. Seasonal changes, food, temperature, water quality and environmental 1094 
enrichment are all factors that have been suggested to affect the quality and quantity of X. 1095 
leavis eggs (Delpire et al., 2011; Godfrey and Sanders, 2004; Green, 2002; Hilken et al., 1096 
1995; Sigel, 1990; Wu and Gerhart, 1991). Although some of these effectors are difficult to 1097 
control, they can be minimised by maintaining a 12 h light/12 h dark cycle, a constant 1098 
temperature (21-23oC), feeding once every 2-3 days, enriching the environment with 1099 
functional items for the frogs (e.g. plastic plants, logs, dishes etc.) and careful monitoring of 1100 
water quality. 1101 
 1102 
NP exposure in X. laevis embryos 1103 
 NP exposure time in X. laevis embryos is an important consideration for this protocol. 1104 
Embryos must be exposed to NPs for a sufficient length of time in order for the key internal 1105 
organs to be exposed to the nanomaterial being tested. It is also important to consider at what 1106 
developmental stage the embryos are exposed to these nanomaterials. The described protocol 1107 
can be adapted depending on the aims of the toxicity screen. For example, embryos can be 1108 
exposed to NPs very early on during the developmental process, such as at NF stage 4 and 1109 
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fixed at NF stage 38. Over this time, the embryos are exposed to NPs during key 1110 
developmental processes such as gastrulation (NF stage 10) and neurulation (NF stage 15). 1111 
The NF stage at which the NPs are applied will greatly affect exposure too. For example, 1112 
between NF stages 38-45 the gills and mouth of the embryos are open, providing additional 1113 
routes of exposure for NPs aside from the porous skin, as we have previously discussed 1114 
(Webster et al., 2016). As highlighted in the protocol description, it is essential to confirm 1115 
that the embryos have been exposed to the NPs being tested by the experimental end point, 1116 
which we propose can be done using microscopy (see Support Protocol 5 and Alternate 1117 
Protocol 1). This is of particular importance for nanomaterials that do not produce visible 1118 
toxicity in the embryos. 1119 
 1120 
Anticipated Results 1121 
 NP physical characterization is crucial step in a toxicity evaluation of NP dispersions 1122 
for both in vitro and in vivo experiments. Importantly, it is necessary to evaluate stability and 1123 
size distribution of the NP dispersions in experimental conditions that mimic, as much as 1124 
possible, the conditions similar to those used in the biological nanotoxicity assays (i.e. 1125 
temperature, dispersion medium, NP dose, etc.). Stability of the NP dispersion in its 1126 
dispersing medium does not guarantee that such NPs are equally stable in the media used in 1127 
the biological study. Biological media are complex fluids containing biomolecules and salts 1128 
that can strongly affect NP self-assembly in solution, in some cases also causing 1129 
agglomeration and precipitation. It is known that NP cellular interaction and uptake are 1130 
affected by NP physical properties and size, thus to interpret NP biological response it is 1131 
necessary to know their features in the biological environment. DLS is the best technique to 1132 
investigate the stability of the NP dispersions in different media over time at biologically 1133 
relevant temperatures. It is important to note that this technique provides the hydrodynamic 1134 
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size distribution of the NPs in the solution (highlighting possible aggregation effects), but it 1135 
does not provide the exact size of the single NP. For this reason TEM experiments should be 1136 
done to complement DLS investigation. TEM is an imaging technique that gives information 1137 
on the morphology and size of the NPs, providing exactly the size of the NP units in the 1138 
dispersion. This knowledge permits better interpretation of the DLS results. It is also 1139 
important to underline that TEM sizes are not representative of the NP distribution in 1140 
solution. In fact, the drying process necessary to measure the NPs, could promote 1141 
agglomeration. Nevertheless, qualitative information can be extracted that can be related to 1142 
NP dispersibility. In fact, if the images show single well-separated NPs on the grid, it is 1143 
reasonable to assume that they are also well dispersed in the dispersion. In the same way if 1144 
big NP agglomerates are visible in the grid, it suggests that NPs are also aggregated when 1145 
dispersed in aqueous solutions.   1146 
 Cytototoxicity assessment is an essential step in the described process of NP hazard 1147 
assessment (Fig. i). As detailed above in basic protocol 2, the researcher should select 1148 
cytotoxicity assessment methodologies that are compatible with their nanomaterials of choice 1149 
(see critical parameters section; cell culture considerations for discussion). Ideally the 1150 
selected methodologies should cover >1 cytotoxic assessment parameters (oxidative stress, 1151 
cell death, cell viability and inflammatory response). Here we detail three protocols (basic 1152 
protocol 2, support protocol 2 and support protocol 3) that combined, robustly assess cell 1153 
viability (MTT and trypan blue exclusion assays) and cell death in response to NP treatment, 1154 
providing percentage cell viability readings and an indication of apoptosis by 1155 
immunoblotting. As detailed above, this data is then combined with results from the X. laevis 1156 
phenotypic abnormality assay (basic protocol 3) to provide a hazard ranking score for NP 1157 
safety assessment. 1158 
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 The X. laevis phenotypic abnormality assay (Basic Protocol 3) results in the 1159 
percentage of embryos that did not survive NP exposure and the percentage that display 1160 
phenotypic abnormalities relative to the total number of embryos tested, and therefore 1161 
represents the percentage lethality and percentage abnormality, respectively. Expected 1162 
abnormalities commonly include eye malformations, bent anterior-posterior axis, oedema, 1163 
blistering, stunted growth and pigmentation loss (Table iii). We have previously described 1164 
example results for a range of high-to-low toxicity-inducing nanomaterials (Webster et al., 1165 
2016). As discussed above, comparison between the X. laevis phenotypic abnormality data 1166 
and the cytotoxicity results provides a hazard ranking score for NP safety, which can be used 1167 
to determine whether or not further nanotoxicity assessment in mammalian systems is 1168 
permissible or if further optimisation of NP design/synthesis is first needed to reduce toxicity 1169 
of the developed nanoformulation (Fig. i).  1170 
 1171 
Time Considerations 1172 
 Basic Protocol 1: Preparation of the samples for DLS measurements is a quick 1173 
procedure that generally involves the dilution of the NP stock dispersions in the different 1174 
biological media. A DLS experiment is quite fast, it will take between 5-15 min depending on 1175 
if the measurement is performed at fixed angle or at different angles (in the latter case it will 1176 
be longer). The measurements should be repeated over the experimental time of the 1177 
biological assay with closer repetitions in the first day. Overall, the experimental time 1178 
depends on the sample numbers and duration of the biological experiments. Moreover, 1179 
additional time should be considered for the analysis of DLS data for multi-angle 1180 
measurements for which the operator needs to make some more analysis work after the 1181 
experiments.  1182 
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 Support Protocol 1: Preparation of TEM samples on suitable grids requires at least 1183 
overnight incubation to guarantee complete evaporation of the solvent. Generally, the grids 1184 
will be analysed by a specialized technician, thus the experimental time is not predictable. 1185 
The actual measurement takes approximately half an hour for sample (different areas of the 1186 
grids need to be imaged). After that the operator will need to analyse the images with specific 1187 
imaging softwares for extracting a size distribution of the NPs. The duration of this analysis 1188 
depends on the quality of the images and the properties of the sample, if the NPs are well 1189 
separated usually it is possible with most imaging softwares to automatically measure the size 1190 
of all the NPs. While if the NPs formed agglomerates on the grid, size measurement of each 1191 
single NP has to be done manually and this will take longer time. 1192 
 Basic Protocol 2: Preparation of mammalian cell line stocks, validation and 1193 
preparation of cells for experiments will take 2-3 weeks depending on how well the specific 1194 
cells grow in culture. Seeding/growing cells will take 1 day and NP treatment takes 3 days. 1195 
The MTT assay takes a further 5-6 h (depending on sample numbers) and the 1196 
reading/generation of results ~1-2 h: ~3-4 weeks in total, depending on how well the cell 1197 
lines grow.  1198 
 Support Protocol 2: As stated above for basic protocol 2, cell line preparation, 1199 
seeding and treating with NP will take ~2-3 weeks plus an additional 4 days. The trypan blue 1200 
exclusion assay will take a further 30 min-2 h depending on how many samples are to be 1201 
analysed. Likewise, cell counting will take 10 min-2 h depending on sample numbers and 1202 
count methodology: ~3-4 weeks in total, depending on how well the cell lines grow. 1203 
 Support Protocol 3: Sample preparation including treatment times and protein 1204 
preparation will take ~4-5 days. SDS-PAGE and completion of immunoblotting will then 1205 
take a further 0.5 and 3 days, respectively: ~7-8 days in total, depending on optimised 1206 
conditions.  1207 
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 Basic Protocol 3: Depending on the requirements of the NF stage needed for specific 1208 
experiments, X. laevis embryo exposure and incubation times can vary from a few h to 1209 
several days. This is also influenced by the incubation temperature used (see points 1-4 of 1210 
Basic Protocol 3 for discussion of time estimates).  At the end of the incubation period, fixing 1211 
the embryos can take 2-24 h depending on the temperature used. Washing, mounting, 1212 
imaging and scoring the embryos will take a few hours depending on how many embryos 1213 
need to be analysed. Finally, dehydration of embryos for long-term storage takes ~30-40 min: 1214 
~1 week in total. 1215 
 Support Protocol 4: Priming of females can take up to 1 week and induction of 1216 
ovulation, up to 14 h. Fertilisations and de-jellying will take 2.5 h: ~6-8 days in total. 1217 
 Support Protocol 5: Preparation of imaging plates (1 h) and live, whole-mount 1218 
fluorescent imaging of embryos ~1-3 h (depending on the number of embryos to analyse): 2-1219 
4 h in total. 1220 
 Alternate Protocol 1: Anesthetising, fixing and dehydrating embryos takes 3.5 h in 1221 
total. Embedding the embryos in resin takes 3 days, whilst sectioning, mounting and imaging 1222 
could take up to 2-3 days (depending upon the number of samples to process): ~5.5-6.5 days 1223 
in total. 1224 
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Figure Legends 1362 
 1363 
Figure i: Flow diagram of proposed nanotoxicity screening protocol. This figure is 1364 
adapted from a previously published study from our group (Webster et al., 2016). Briefly, 1365 
newly synthesised nanotherapeutics are firstly characterised in terms of their physicochemical 1366 
characteristics in biologically relevant media (basic protocol 1). Once identified as stable by 1367 
this protocol, NPs are further assessed through an integrated approach of cytotoxicity analysis 1368 
and phenotypic abnormality screening in X. laevis embryos (basic protocol 2 and basic 1369 
protocol 3, respectively). Here we provide detailed methodological descriptions of these three 1370 
protocols as highlighted in the dotted box. Results from basic protocols 2 and 3 are then 1371 
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combined to provide a score that can indicate whether or not further in vivo nanotoxicity 1372 
assessment should be made using mammalian models.  1373 
 1374 
Figure ii: Schematic drawing of a DLS apparatus with a multi-angle detector. The equipment 1375 
is composed of a monochromatic laser in the visible range, optical lenses to focus the beam 1376 
on the sample, attenuator of the incident light, detector (equipped with a motor to move it at 1377 
different angles with respect to the incident beam), correlator and PC with a specific software 1378 
for the analysis of the raw data. The attenuator modulates the incident light to an optimal 1379 
value that depends on the features of the detector. The detected scattered light reaches the 1380 
correlator that builds an auto-correlation function of the scattered intensity for each angle. 1381 
The auto-correlation functions and the raw signals (kcounts/s) can be analyzed by the specific 1382 
software provided by the supplier of the Instrument. 1383 
 1384 
Figure iii: Suggested X. laevis NF stages for NP exposure. Schematic depicts X. laevis 1385 
embryos at different developmental NF stages that have been selected for treatment to assess 1386 
nanotoxicity (Webster et al., 2016). Embryo physiology images (Nieuwkoop and Faber, 1387 
1967) depicted above the line, with their associated NF staging description provided below 1388 
the line. Images not to scale. The selected NF stages for NP exposure provide analysis of two 1389 
critical teratogenic assessment stages; gastrulation (NF 4-NF 38) and neuralation (NF 15-NF 1390 
38), and at stages that can more accurately represent an adult system during organogenesis 1391 
(NF 38-45).  1392 
